IN2014DN11272A - - Google Patents

Info

Publication number
IN2014DN11272A
IN2014DN11272A IN11272DEN2014A IN2014DN11272A IN 2014DN11272 A IN2014DN11272 A IN 2014DN11272A IN 11272DEN2014 A IN11272DEN2014 A IN 11272DEN2014A IN 2014DN11272 A IN2014DN11272 A IN 2014DN11272A
Authority
IN
India
Prior art keywords
recombinant
protein
mammalian cells
present
fge
Prior art date
Application number
Other languages
English (en)
Inventor
Chun Zhang
Ferenc Boldog
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of IN2014DN11272A publication Critical patent/IN2014DN11272A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN11272DEN2014 2012-06-29 2013-06-28 IN2014DN11272A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666712P 2012-06-29 2012-06-29
PCT/US2013/048601 WO2014005036A1 (en) 2012-06-29 2013-06-28 Method of producing recombinant iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
IN2014DN11272A true IN2014DN11272A (enExample) 2015-10-09

Family

ID=49778402

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11272DEN2014 IN2014DN11272A (enExample) 2012-06-29 2013-06-28

Country Status (21)

Country Link
US (1) US20140004097A1 (enExample)
EP (1) EP2867367A4 (enExample)
JP (1) JP2015523074A (enExample)
KR (1) KR20150037908A (enExample)
CN (1) CN104583414A (enExample)
AU (1) AU2013282417A1 (enExample)
BR (1) BR112014032544A2 (enExample)
CA (1) CA2877492A1 (enExample)
CL (1) CL2014003569A1 (enExample)
CO (1) CO7240395A2 (enExample)
CR (1) CR20140587A (enExample)
DO (1) DOP2014000297A (enExample)
EA (1) EA201492185A1 (enExample)
HK (2) HK1209458A1 (enExample)
IL (1) IL236324A0 (enExample)
IN (1) IN2014DN11272A (enExample)
MX (1) MX2015000188A (enExample)
PE (1) PE20150603A1 (enExample)
PH (1) PH12014502870A1 (enExample)
SG (1) SG11201408755TA (enExample)
WO (1) WO2014005036A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
AU2015219339B2 (en) * 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
EP3253884B1 (en) * 2015-02-05 2020-03-18 R.P. Scherer Technologies, LLC Activated formylglycine-generating enzymes and methods of producing and using the same
CA3001483A1 (en) * 2015-10-07 2017-04-13 Joel HUIZENGA Resetting biological pathways for defending against and repairing deterioration from human aging
WO2017083306A1 (en) 2015-11-09 2017-05-18 R.P. Scherer Technologies, Llc Anti-cd22 antibody-maytansine conjugates and methods of use thereof
CA3032099A1 (en) * 2016-07-25 2018-02-01 Repligen Corporation Alternating tangential flow rapid harvesting
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
CA2368797C (en) * 1999-04-26 2010-08-17 Genentech, Inc. Cell culture process
US6890736B1 (en) * 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
CN110496230A (zh) * 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20050019914A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
CA2609060C (en) * 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
ES2434494T3 (es) * 2005-12-08 2013-12-16 Amgen, Inc. Células huésped mejoradas y métodos de cultivo
PL3219795T3 (pl) * 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
JP2013507131A (ja) * 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
KR20130043165A (ko) 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase

Also Published As

Publication number Publication date
HK1209458A1 (en) 2016-04-01
SG11201408755TA (en) 2015-02-27
PH12014502870A1 (en) 2015-02-23
MX2015000188A (es) 2015-04-08
CR20140587A (es) 2015-04-06
EP2867367A4 (en) 2016-02-24
KR20150037908A (ko) 2015-04-08
CN104583414A (zh) 2015-04-29
HK1209790A1 (en) 2016-04-08
CA2877492A1 (en) 2014-01-03
EP2867367A1 (en) 2015-05-06
CO7240395A2 (es) 2015-04-17
PE20150603A1 (es) 2015-05-27
JP2015523074A (ja) 2015-08-13
US20140004097A1 (en) 2014-01-02
BR112014032544A2 (pt) 2017-08-01
CL2014003569A1 (es) 2015-04-17
EA201492185A1 (ru) 2015-10-30
WO2014005036A1 (en) 2014-01-03
AU2013282417A1 (en) 2015-01-29
IL236324A0 (en) 2015-02-26
DOP2014000297A (es) 2015-04-15

Similar Documents

Publication Publication Date Title
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
MX355650B (es) Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
AU2019268194A1 (en) Cell culture system
MX2021008142A (es) Metodos para cosechar cultivos de celulas de mamifero.
PE20150957A1 (es) Celulas para producir iduronato-2-sulfatasa recombinante
MX344970B (es) Medio de cultivo celular para la expresion de la proteina adamts.
MX2013005853A (es) Enzimas de fusion que tienen actividad de n-acetilglucosaminil transferasa.
MY181513A (en) Cell culture compositions and methods for polypeptide production
EP3763810A3 (en) T cell modifying compounds and uses thereof
WO2013009648A3 (en) Cell culture process
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
PH12014501019A1 (en) Kit comprising serum replacement and labile factors
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
IN2014CN02963A (enExample)
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
AU2018276376A1 (en) Cell culture methods
MX2010005079A (es) Metodos para medir la viabilidad celular sin usar celulas de control.
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
WO2015117033A3 (en) Methods of increasing protein production in mammalian cells